Bristol-Myers drops Hepatitis C dual regimen in U.S. By: MarketWatch October 07, 2014 at 11:15 AM EDT Company will not pursue FDA approval amid ‘rapidly evolving’ treatment landscape. Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences